---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-004750"
form_type: "8-K"
ticker: "VYCO"
cik: "0001424768"
company_name: "VYCOR MEDICAL INC"
filed_at: "2025-04-15T23:59:59+00:00"
generated_at: "2026-05-23T14:26:06.015130+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Vycor Medical reports 2024 revenue up 9% to $1.59M; engages Maxim Group for strategic growth

## Summary
- Revenue $1,589,324 (+9% YoY); Vycor Medical division revenue up 10% to $1,515,744.
- Gross margin 89%; non-GAAP cash operating expenses $1.34M (+$136K); non-GAAP operating profit $81,548 down from $111,084.
- US hospital sales up 17% with 11 new hospitals; eight new peer-reviewed studies published on ViewSite Brain Access System.
- Engaged Maxim Group LLC to assist with corporate strategy including M&A, partnerships, and potential uplisting to a US exchange.
- Products manufactured in US; tariffs not expected to directly impact costs but may affect exports and raw material supply.

## SEC filing metadata
- accession: 0001641172-25-004750
- form_type: 8-K
- ticker: VYCO
- cik: 0001424768
- company_name: VYCOR MEDICAL INC
- filed_at: 2025-04-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1424768/000164117225004750/0001641172-25-004750-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1424768/000164117225004750/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-004750
- JSON: https://secwatch.observer/filing/0001641172-25-004750.json
- Plain text: https://secwatch.observer/filing/0001641172-25-004750.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.